Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gene sequence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Gene sequence. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2022-001092-14 Sponsor Protocol Number: TIGEM5_USH Start Date*: 2023-10-12
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: A phase I/II open label, dose escalation study of sub-retinal administration of a “mixture of two adeno-associated viral vectors of serotype 8 containing the 5 ´- half sequence of the human MYO7A ...
    Medical condition: Usher syndrome (USH) is characterized by the association of sensorineural hearing loss, Retinitis Pigmentosa (RP), and, in some cases, vestibular dysfunction. It is the most frequent cause of deaf-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10063396 Usher's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10063396 Usher's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004427-37 Sponsor Protocol Number: ESPP001 Start Date*: 2014-10-01
    Sponsor Name:PARENT PROJECT ONLUS
    Full Title: Multicentre, randomised, double-blind, dose titration design in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen (200 mg bid)...
    Medical condition: Restrictive respiratory syndrome with frequent pulmonary infections and cardiomyopathy. wasting of skeletal muscle, severe local inflammation and, at least initially, muscle regeneration.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10064571 Gene mutation PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003947-51 Sponsor Protocol Number: M14POS Start Date*: 2014-10-06
    Sponsor Name:NKI-AVL
    Full Title: Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone rece...
    Medical condition: Hormone receptor positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Temporarily Halted) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001335-12 Sponsor Protocol Number: D5160C00030 Start Date*: 2016-05-12
    Sponsor Name:Hellenic Oncology Research Group
    Full Title: A longitudinal study evaluating molecular changes associated with resistance to first and third (AZD9291) generation EGFR TKIs in patients with EGFR mutant NSCLC using "liquid biopsy"
    Medical condition: Patients with NSCLC
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000673-68 Sponsor Protocol Number: 16IC17 Start Date*: 2018-10-09
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Phase I/II study of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan
    Medical condition: Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10069566 Severe combined immunodeficiency syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-000562-36 Sponsor Protocol Number: BIG2-06/N063D/EGF106708 Start Date*: 2007-05-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their comb...
    Medical condition: Operable primary breast cancer with over expression/ amplification of HER2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) HU (Completed) FR (Completed) GB (Completed) SK (Completed) EE (Completed) CZ (Completed) DK (Completed) BE (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed) ES (Completed) SI (Completed) BG (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002028-26 Sponsor Protocol Number: AK0529-1003 Start Date*: Information not available in EudraCT
    Sponsor Name:Ark Biosciences Pty Ltd.
    Full Title: A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing ...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004733-17 Sponsor Protocol Number: XAMNPEAP2019 Start Date*: 2020-02-25
    Sponsor Name:Aurora Pujol Onofre
    Full Title: Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002873-88 Sponsor Protocol Number: MGT-RPGR-021 Start Date*: 2022-07-19
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) NL (Ongoing) BE (Completed) ES (Ongoing) FR (Completed) DK (Completed) DE (Prematurely Ended) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-004527-31 Sponsor Protocol Number: GS-US-196-0103 Start Date*: 2008-12-12
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and...
    Medical condition: Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001928-19 Sponsor Protocol Number: C12-2 Start Date*: 2014-01-23
    Sponsor Name:GERCOR
    Full Title: Multi-Line Therapy Trial in Unresectable Wild-Type KRAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III study.
    Medical condition: Unresectable Wild-Type KRAS Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002766-20 Sponsor Protocol Number: CAUY922A2101 Start Date*: 2009-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in...
    Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004252-40 Sponsor Protocol Number: CEPO906A2209 Start Date*: 2005-09-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer
    Medical condition: Non-small cell lung cancer (NSCLC) - patients with inoperable stage IIIb or IV NSCLC have a very poor prognosis, with overall survival of 4-8 months.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005080-40 Sponsor Protocol Number: FLT180a-04 Start Date*: 2018-05-15
    Sponsor Name:Freeline Therapeutics Limited
    Full Title: An Open-Label, Multicentre, Long-Term Follow-Up Study to Investigate the Safety and Durability of Response Following Dosing of a Novel Adeno-Associated Viral Vector (FLT180a) in Patients with Haemo...
    Medical condition: Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-002605-10 Sponsor Protocol Number: CJDQ443B12301 Start Date*: 2022-04-01
    Sponsor Name:Novartis Pharma AG
    Full Title: KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic K...
    Medical condition: Advanced non-small cell lung cancer harboring the KRAS G12C mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Trial now transitioned) ES (Ongoing) NO (Completed) GR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) DK (Completed) SI (Trial now transitioned) EE (Completed) IT (Trial now transitioned) PL (Completed) HR (Completed) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006459-10 Sponsor Protocol Number: KU36-58 Start Date*: 2007-07-18
    Sponsor Name:KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies)
    Full Title: A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associat...
    Medical condition: Advanced ovarian cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000657-31 Sponsor Protocol Number: EMCR2015-7741 Start Date*: 2019-09-05
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer.
    Medical condition: unresectable stage IIIc and IV melanoma (including unknown primary, mucosal and uveal melanoma), and unresectable recurrent/metastatic(R/M) HNSCC.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002181-12 Sponsor Protocol Number: STEP Start Date*: 2019-09-30
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: EXPLORING OPTIMAL SEQUENCE TREATMENT IN HER2+ PERTUZUMAB PRE- TREATED ADVANCED BREAST CANCER PATIENTS. THE STEP TRIAL.
    Medical condition: HER2 POSITIVE METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10025541 Malignant breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001982-42 Sponsor Protocol Number: J004 Start Date*: 2012-08-02
    Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust
    Full Title: Investigation of a novel intervention in Acute HIV infection (AHI) on long term latent HIV reservoir size: A pilot study of antiretroviral therapy plus immunoglobulin in AHI
    Medical condition: Acute HIV Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10000811 Acute infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005112-17 Sponsor Protocol Number: IRFMN-BRC-7103 Start Date*: 2017-07-11
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Multicenter, randomized, phase II study of neoadjuvant chemotherapy associated or not with zoledronate and atorvastatin in triple negative breast cancers - YAPPETIZER Study
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 11:31:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA